The New Revolutionary: Ovid's Levin On Pioneering In Neurology
Emerging Company Profile: Orphan disease-focused Ovid Therapeutics, with $80m in VC financing in the bag and an alliance with Takeda, recently raised $75m in a US initial public offering. Scrip spoke with CEO Jeremy Levin and chief business and finance officer Yaron Werber before the recent IPO about how the young biotech firm intends to become a successful neurology company.
You may also be interested in...
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.